RADT-15. THE ROLE OF STEREOTACTIC RADIOSURGERY IN WHO GRADE II MENINGIOMAS: RESULTS FROM A LARGE EUROPEAN MULTICENTER STUDY

Abstract BACKGROUND This study evaluates the outcomes of WHO grade II meningiomas treated with stereotactic radiosurgery (SRS) using a large, multi-institutional European database. We aim to investigate the long-term tumor control rate and morbidity associated with SRS. METHODS Data from 355 consecutive patients treated between 1992 and 2022 at 16 European radiosurgery centers were retrospectively analyzed. After excluding 40 patients due to loss to follow-up, results from 315 patients were included. Clinical and imaging data were independently collected by each center and uniformly entered into a multicenter database. RESULTS The median age of patients was 56 years, with 54% being female. The median follow-up duration was 46.3 ± 36.9 months. Tumors had prior surgical treatment and biopsy in 99% and 1% of cases, respectively. Tumors received previous radiotherapy or SRS in 27.4% of cases. SRS was performed due to local progression in 89.6% of cases, residual tumor in 6.4%, and distant progression in 4.0%. SRS characteristics included a median target volume of 5.1 cm³ and a median margin dose of 16 Gy (53.5% isodose). The 3-year local control rate was 72.0%, with a progression-free survival rate of 66.6% and an overall survival rate of 89.7%. Transient and permanent morbidity rates were 6.4% and 3.5%, respectively. Multivariate analysis identified previous radiotherapy and age as significant factors influencing these outcomes. CONCLUSIONS This study is the largest to date on SRS in WHO grade II meningiomas. Our data shows that SRS is a viable and safe treatment option for residual and recurrent WHO grade II meningiomas

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2024-11-01
DOI
https://doi.org/10.1093/neuonc/noae165.0299
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RADT-15. THE ROLE OF STEREOTACTIC RADIOSURGERY IN WHO GRADE II MENINGIOMAS: RESULTS FROM A LARGE EUROPEAN MULTICENTER STUDY

Otto Bundschuh, Christer Lindquist, Roman Liščák, Ian Sabin et al.
Neuro-Oncology
Meningioma and schwannoma management
article

RADT-15. THE ROLE OF STEREOTACTIC RADIOSURGERY IN WHO GRADE II MENINGIOMAS: RESULTS FROM A LARGE EUROPEAN MULTICENTER STUDY

Otto Bundschuh, Christer Lindquist, Roman Liščák, Ian Sabin, R Martínez Álvarez, Tobias Greve, Constantin Tuleasca, Theresa Hofmann, Piero Picozzi, Jason S. Frischer, Aurélia Kollová, Thomas Mindermann, Hans‐Jakob Steiger, Bodo Lippitz, Jean Marie Régis, Christian Ewelt, Andrea Franzini, Makoto Nakamura, Albertus T.C. van Eck, F. Unger, Antonio Santacroce, Felix Ehret, Marc Lewitz, Bente Sandvei Skeie, Alexander Muacevic, Arthur Adolfo Nicolato, Mainar Longhi, Gerhard A. Horstmann, Enrico Motti, Matthias Radatz, S Zafy Alsofy, S Faedo, S Masaranov
article en

Abstract

Abstract BACKGROUND This study evaluates the outcomes of WHO grade II meningiomas treated with stereotactic radiosurgery (SRS) using a large, multi-institutional European database. We aim to investigate the long-term tumor control rate and morbidity associated with SRS. METHODS Data from 355 consecutive patients treated between 1992 and 2022 at 16 European radiosurgery centers were retrospectively analyzed. After excluding 40 patients due to loss to follow-up, results from 315 patients were included. Clinical and imaging data were independently collected by each center and uniformly entered into a multicenter database. RESULTS The median age of patients was 56 years, with 54% being female. The median follow-up duration was 46.3 ± 36.9 months. Tumors had prior surgical treatment and biopsy in 99% and 1% of cases, respectively. Tumors received previous radiotherapy or SRS in 27.4% of cases. SRS was performed due to local progression in 89.6% of cases, residual tumor in 6.4%, and distant progression in 4.0%. SRS characteristics included a median target volume of 5.1 cm³ and a median margin dose of 16 Gy (53.5% isodose). The 3-year local control rate was 72.0%, with a progression-free survival rate of 66.6% and an overall survival rate of 89.7%. Transient and permanent morbidity rates were 6.4% and 3.5%, respectively. Multivariate analysis identified previous radiotherapy and age as significant factors influencing these outcomes. CONCLUSIONS This study is the largest to date on SRS in WHO grade II meningiomas. Our data shows that SRS is a viable and safe treatment option for residual and recurrent WHO grade II meningiomas

Neuro-OncologyVol. 26(Supplement_8)
Witten/Herdecke University (DE), University of Milan (IT), Medical University of Graz (AT), Haukeland University Hospital (NO), Royal Hallamshire Hospital (GB), LMU Klinikum (DE), Hirslanden Klinik Im Park (CH), Na Homolce Hospital (CZ), University Hospital Münster (DE), Queen Square Radiosurgery Centre (GB), The Wellington Hospital (GB), Bupa Cromwell Hospital (GB), Hospital Ruber Internacional (ES), University Hospital Cologne (DE), IRCCS Humanitas Research Hospital (IT), Centrum Gamma Knife (PL), Digital Research Alliance of Canada, Heinrich Heine University Düsseldorf (DE), Medical University of Vienna (AT), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Openalex Percentile: Top 70%
Meningioma and schwannoma management
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.